Chest
Volume 132, Issue 2, August 2007, Pages 617-623
Journal home page for Chest

Original Research
Chest Imaging
The Effects of Radiation Dose and CT Manufacturer on Measurements of Lung Densitometry

https://doi.org/10.1378/chest.06-2325Get rights and content

Background

To evaluate the effect of radiation dose and scanner manufacturer on quantitative CT scan measurements of lung morphology in smokers.

Methods

Low-dose and high-dose, inspiratory, multislice CT scans were obtained in 50 subjects at intervals of approximately 6 months (mean [± SD] interval, 0.5 ± 0.2 years). In another 30 subjects, multislice CT scans were acquired first using a GE LightSpeed Ultra (General Electric Healthcare; Milwaukee, WI), followed a mean time of 1.2 ± 0.4 years later by using a Siemens Sensation 16 scanner (Siemens Medical Solutions; Erlangen, Germany). Custom software was used to measure lung volume, mass, mean density, and the extent of emphysema using threshold cutoffs of −950, −910, and −856 Hounsfield units (HU) and the lowest 15th and 5th percentile points.

Results

The change in radiograph dose significantly affected measurements of emphysema assessed using mean lung density, threshold, or percentile methods. There were also interactions between dose and total lung volume for all of the measurements except the −950-HU threshold and the lowest fifth percentile point. These two emphysema measurements suggest that there was more emphysema found in the CT scans obtained using a lower radiograph dose. Only the mean lung density and −856-HU threshold showed significant effects between CT scanner manufacturers and interactions between total lung volume and scanner. All other measures of lung structure were not different between the two CT scanners.

Conclusion

CT scan measurements of very low density lung structures are significantly affected by radiation dose but are less sensitive to the lung volume. Image acquisition parameters including radiation dose, scanner type, and the subject's breath size should be standardized to estimate emphysema severity in longitudinal studies.

Section snippets

Subject Selection

Subjects for this study were selected from the British Columbia Cancer Agency Lung Health Study.20 The study was approved by the clinical ethics review boards of the British Columbia Cancer Agency and the University of British Columbia. All subjects signed informed consent forms to allow their spirometry and CT scan images to be used for research. This study comprises a cohort of heavy smokers who have been screened for the presence of lung nodules using “low-dose” CT scans. If suspicious

Subjects

The subjects' demographic data are summarized in Table 1 . There were more men in the CT dose study than in the CT scanner manufacture study, and there were more current smokers than former smokers in each study group. There were no significant differences (p > 0.05) in the spirometry measurements between study groups.

Radiation Dose Study

A summary of the measurements of total lung volume, total lung mass, mean lung density, %Emphysema, and percentile points obtained using the low-dose and high-dose CT scan images

Discussion

Quantitative CT scan imaging has become a very important tool for quantifying the extent of emphysema in subjects with COPD. However, most published studies arise from a single institution scanning small numbers of subjects using a single CT scanner and a site-specific scanning protocol. It is now apparent that to advance the knowledge of how the lung changes with time, either in a diseased state or with an intervention, quantitative CT scanning must be applied to larger cohorts acquired from

ACKNOWLEDGMENT

The authors wish to acknowledge Dr. Elizabeth Tench for statistical analysis; Anh-Toan Tran and Ida Chan, MD, for technical assistance in developing and supporting the lung analysis application; and Claudine Storness-Bliss, Dianna Louie, and Sukhinder Khattra for logistical assistance.

References (35)

  • I Orlandi et al.

    Spirometric-gated computed tomography quantitative evaluation of lung emphysema in chronic obstructive pulmonary disease: a comparison of 3 techniques

    J Comput Assist Tomogr

    (2004)
  • DS Gierada et al.

    Repeatability of quantitative CT indexes of emphysema in patients evaluated for lung volume reduction surgery

    Radiology

    (2001)
  • RJ Lamers et al.

    Chronic obstructive pulmonary disease: evaluation with spirometrically controlled CT lung densitometry

    Radiology

    (1994)
  • GA Gould et al.

    Parenchymal emphysema measures by CT lung density correlates with lung function in patients with bullous disease

    Eur Respir J

    (1993)
  • PA Gevenois et al.

    Comparison of computed density and macroscopic morphometry in pulmonary emphysema

    Am J Respir Crit Care Med

    (1995)
  • PA Gevenois et al.

    Comparison of computed density and microscopic morphometry in pulmonary emphysema

    Am J Respir Crit Care Med

    (1996)
  • GA Gould et al.

    CT measurements of lung density in life can quantitate distal airspace enlargement-an essential defining feature of human emphysema

    Am Rev Respir Dis

    (1988)
  • Cited by (119)

    • Quantitative CT of Interstitial Lung Disease

      2019, Seminars in Roentgenology
      Citation Excerpt :

      However, there are many important CT protocol issues common to both VCT and QCT imaging of the lungs including instructing the patient to breathe to the proper lung volume and having the patient remains entirely still, while holding their breath in order for the CT scanner to obtain all of the projection data to accurately reconstruct the images.5 The patient dose, lung volume, and CT scanner type can affect the accuracy of the CT lung density measurements.6 The patient should be positioned in the center of the CT gantry and their arms should be above their heads.

    View all citing articles on Scopus

    This work was supported by National Cancer Institute grants N01-CN-85188, 1U01-CA-96109 and P01–96964 (to Dr. Lam); a Canadian Institutes of Health Research-Industry Partnership Grant (GlaxoSmithKline) No. DOP#76813 (PDP), and a British Columbia Lung Association/Canadian Institutes of Health Research New Investigator Award (to Dr. Coxson).

    Dr. Coxson has received honoraria, consultant fees, and contract service agreements from GlaxoSmithKline for research studiesinvolving quantitative CT scanning and COPD. A percentage of his salary between 2003 and 2006 derived from contract funds provided to a colleague (Dr. Paré) by GlaxoSmithKline for the development of validated methods to measure emphysema and airway disease using CT scanning. There is no financial relationship between any industry and the current study. Dr. Paré is the principal investigator of a project jointly funded by the Canadian Institute of Health Research (CIHR) and GlaxoSmithKline (one third by the CIHR and two thirds by industry). This grant application was funded after peer review by the regular CIHR mechanism, and the funds received from industry are directly related to the operating costs of the study. Dr. Paré is also principal investigator of a Merck Frosst-supported research program to investigate gene expression in the lungs of patients who have COPD. These funds have supported the technical personnel and expendables involved in the project. Dr. Hogg served as a consultant to Altana Pharmaceuticals in 2003, 2004, and 2005, and also served on the Canadian advisory board for GlaxoSmithKline for 1 year in 2003. He has participated as a speaker in scientific meetings and courses organized and financed by various pharmaceutical companies including AstraZeneca, Altana Pharmaceuticals, and GlaxoSmithKline. He serves as the principal investigator on a grant jointly funded by the CIHR and GlaxoSmithKline (one third by the CIHR and two thirds by industry). This grant application was funded after peer review by the regular CIHR mechanism, and the funds received from industry are directly related to the operating costs of the study. Drs. Yuan, Mayo, Lam, and McWilliams have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

    View full text